In 1993, there was no established standard adjuvant treatment for melanoma patients. The results of the ECOG trial 1684 on highdose interferon were not available, and all other randomized adjuvant treatment trials with chemotherapy as well as biological agents did not suggest a benefit. The search for adjuvant treatments was clearly indicated.
For metastatic melanoma, DTIC was the only widely licensed compound. Cisplatin is another active agent, however, cisplatininduced remissions were usually short-lived. Tamoxifen had been used in non-randomized trials as single agent or in addition to DTIC or cisplatin-based polychemotherapy. A small randomized trial reported by Cocconi suggested a survival benefit for patients with metastatic melanoma, if tamoxifen was added to DTIC (Cocconi et al, 1992) . There was no further information from randomized studies concerning an effect of tamoxifen in addition to chemotherapy, although several uncontrolled phase II trials suggested a high response rate (however within the confidence limits of other polychemotherapy regimens) of treatment with chemotherapy and tamoxifen in patients with metastatic melanoma (DelPrete et al, 1984; McClay et al, 1987) . Preclinical studies from the group of McClay described a synergistic interaction between cisplatin and tamoxifen (McClay et al, 1993) .
In order to study a possible effect of cisplatin and tamoxifen as adjuvant treatment on survival of melanoma patients, a randomized controlled adjuvant trial protocol would have been logical in view of the information available at that time.
Knowing the information available today, there is no remaining strong rationale to study cisplatin and tamoxifen as adjuvant treatment in melanoma patients. For metastatic melanoma, a larger randomized study suggested no significant effect of cisplatin added to a combination of DTIC and vinblastin, although there was a favourable trend for an improved response-rate and timeto-progression (Jungnelius et al, 1998) . If cisplatin is added to interferon and interleukin 2, the response-rate and time-toprogression can be doubled in patients with metastatic melanoma, but this is again without effect on survival, as shown in a randomized EORTC study (Keilholz et al, 1997) . Regarding tamoxifen, two larger randomized studies have proven its inefficiency if added to cisplatin-containing chemotherapy in advanced melanoma (Rusthoven et al, 1996; Agarwala et al, 1999 ). An important recent ECOG study comparing DTIC single-agent treatment to a combination of DTIC, cisplatin, BCNU and tamoxifen revealed a (non-significant) doubling in response-rate and no effect on survival in 240 patients with metastatic melanoma (Chapman et al, 1999) .
QUESTION 2

What type of conclusions is possible from an adjuvant non-randomized phase II clinical trial?
Uncontrolled open phase II trials are designed to test the activity and/or the toxicity of a single drug-regimen. Generally a total of 20-50 patients are recruited in these studies. Therefore this design is acceptable for treatment of patients with measurable disease. Only in case of new treatment modalities (e.g. vaccines), the proof of principle with regard to biological end-points should be assessed in the setting of phase I and II trials. For multidrug regimens, where the feasibility and activity represent the major end-points, it is recommended to perform randomized phase II/III trials. Feasibility of administration of cisplatin and tamoxifen was not an issue in this study, since, as the authors state themselves, many hundreds of patients had already received this combination, and the toxicity is well known. Treatment efficacy would therefore have been the only reasonable end-point.
McClay and colleagues do not provide a statistical rationale for their study. As a consequence, 153 patients were enrolled without justification for the patient number. Furthermore, the interval
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between surgery and initiation of chemotherapy is not defined. It is only stated that the scans to exclude further tumour metastases were to be done within 1 month of initiation of treatment. Unspecified is the time interval between surgery and enrolment into the study and no information is provided on the actual interval between surgery and enrolment. The possible exclusion of early relapsers might have improved survival as it may have excluded an adverse prognosis group of patients.
QUESTION 3
What can we learn by comparing survival data from a non-randomized adjuvant trial to historical controls?
The immediate answer of a statistician would be: nothing! There are examples in the literature, where survival analyses from uncontrolled trials in melanoma patients with metastatic disease were used to define prognostic factors for randomized studies (e.g. Balch et al, 1983; Ahmann et al, 1989; Creagan et al, 1990; Barth et al, 1995; Keilholz et al, 1998) , or to develop hypotheses, but these analyses were performed retrospectively, on data from patients treated within clinical trials performed with another justification.
Regarding adjuvant treatments, an example on how misleading survival data from uncontrolled phase II trials can be is the situation in the field of high-dose chemotherapy for patients with breast cancer. Comparison of phase II survival information with historical controls had suggested a survival benefit achieved with high-dose chemotherapy, however, this was not reproducible in randomized studies, because in the randomized studies the survival data of conventional treatment were much better than the historical controls.
An example regarding the change of control groups over time even in controlled randomized studies is illustrated in the development of adjuvant high-dose interferon treatment for melanoma. When the ECOG analysed their trial 1690 , which had been designed to confirm the trial 1684 (Kirkwood et al, 1996) , the survival curves of the high-dose interferon arms of both trials were found to be identical. However, the survival curve of the control group of the 1690 trial was identical to the treatment group, and significantly better than the control group of the 1684 trial. Numerous factors are being discussed, which may have caused the improved survival of the control group in the newer study. As this discussion is ongoing, it is evident that comparison with historical controls is not appropriate for drawing conclusions from adjuvant treatment studies.
A third important example is derived from the development of combination chemotherapy for patients with metastatic melanoma. It took 15 years from the initial favourable report of the fourdrug regimen DBCT (dacarbacine, BCNU, cisplatin, tamoxifen, delPrete et al, 1984) to perform the decisive randomized study proving that this combination did not result in improved survival in patients with advanced melanoma (Chapman et al, 1999) . However, during these 15 years the DBCT regimen had been widely adopted on the basis of uncontrolled phase II data.
CONCLUSIONS
There is no evidence that patients with melanoma may benefit from adjuvant chemotherapy and the report by McClay et al does not change this situation. This uncontrolled study only shows the overall outcome, in terms of disease-free survival and survival, with surgically resected melanoma of stages II, III and IV. The patients represent a selected patient population, as they all had an initial performance status of 0 and an unspecified interval between surgery and initiation of chemotherapy. Such descriptive survival curves do not allow for any firm conclusions to be made regarding efficacy of adjuvant therapy. In order to develop efficient treatments for melanoma patients, we should all continue to make every possible effort to enter patients into controlled adjuvant trials.
